Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data

Xencor stock catapulted Monday to a nearly four-year high, briefly breaking out on positive results in kidney cancer.

Investors Business Daily • Oct 26, 2026

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer

Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for planned late-stage development and expects to begin a registration-enabling study in 2027.

MarketBeat • Oct 26, 2026

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

At the ESMO Congress 2026, Xencor Inc. (NASDAQ:XNCR) shared updated results from the Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC).

Benzinga • Oct 26, 2026

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript

Seeking Alpha • Oct 26, 2026

Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway

Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg, supporting advancement toward FDA Accelerated Approval discussions in 1H 2027 and a phase 3 trial by late 2027. The company is expanding XmAb819 into other ENPP3+ solid tumors and progressing XmAb942 in phase 2b for ulcerative colitis, with interim data expected by end of 2026.

Seeking Alpha • Oct 26, 2026

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comp.

Business Wire • Oct 25, 2026

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC). The live webcast of the conference call may.

Business Wire • Oct 19, 2026

Xencor: Better Funding For Obexelimab

Xencor's antibody platform supports its in-house oncology and immunology pipeline. XNCR's settlement with Alexion helped improve its runway, which should be enough to reach obexelimab's FDA PDUFA decision. Obexelimab's FDA decision is for IgG4-related disease, although XNCR would capture royalties and milestones since it's a partnered asset.

Seeking Alpha • Oct 7, 2026

Xencor to Present at the 2026 Cantor Global Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor's website located at w.

Business Wire • Sep 2, 2026

Xencor Reports Second Quarter 2026 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. “We are excited to present XmAb819 results at ESMO this fall and for other fast-approaching key milestones across our wholly owned clinical pipeline,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “E.

Business Wire • Aug 5, 2026